| Serial Number | 90046614 |
| Word Mark | CAPSIDA BIOTHERAPEUTICS |
| Filing Date | Friday, July 10, 2020 |
| Status | 748 - STATEMENT OF USE - TO EXAMINER |
| Status Date | Friday, March 6, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 7, 2023 |
| Goods and Services | Pharmaceutical research and development in the field of gene therapy; development of pharmaceutical preparations for use in gene therapy and gene delivery technology; development of products being genetic therapies; scientific research in the field of genetic engineering, biotechnology research services, and research and development of new products in the field of gene therapeutics and research tools; research and development in the biotechnology field; scientific and medical research and development in the field of cardiovascular, central nervous system, neurological, ophthalmologic, and peripheral nervous system diseases and disorders and complications associated therewith; scientific research and product development services for others in the pharmaceutical, biotechnology, and medical fields; testing, inspection, research, or development of pharmaceutical preparations for gene therapy and gene delivery technology; biomedical research and development, scientific research and development, pharmaceutical research and development and product development services in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies, gene delivery technologies, and effectors to regulate, modulate, and characterize disease states; biomedical research in the field of gene therapy design and delivery; gene therapy design and product delivery development of biochemical assays; biomedical research and development, scientific research and development, pharmaceutical research and development and product development in the fields of cardiovascular, central nervous system, neurological, ophthalmologic, and peripheral nervous system diseases and disorders; medical services, namely, scientific research in the fields of genetic engineering and gene therapy services; medical services, namely, scientific research in the nature of gene therapy design and delivery services in the field of genetic diseases and disorders |
| NOT AVAILABLE | "BIOTHERAPEUTICS" |
| Pseudo Mark | CAPSIDA BIO THERAPEUTICS |
| Goods and Services | Pharmaceutical preparations for use in gene therapy; pharmaceutical preparations for use in gene delivery technology for use in the treatment of central nervous system, neurological, and peripheral nervous system diseases and disorders; pharmaceutical preparations for use in the treatment of gene therapy treatable diseases for use in the treatment of central nervous system, neurological, and peripheral nervous system diseases and disorders; gene therapy and prophylaxis products, namely, gene transfer, regulation, modulation and delivery pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations that facilitate administration of other pharmaceutical preparations into the brain for enhanced treatment of disorders of the central nervous system, in the nature of drug delivery agents consisting of viral capsids that facilitate the delivery of the preparations; pre-filled vials containing pharmaceutical preparations for the treatment of central nervous system, neurological, and peripheral nervous system diseases and disorders and complications associated therewith |
| Goods and Services | Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences; Chemical and biochemical products for use in gene delivery technology namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, vectors, promotors, enhancers and other regulatory sequences for development of therapeutics and the treatment of cardiovascular, central nervous system, neurological, and peripheral nervous system diseases and disorders; Chemical and biochemical products for use in gene delivery technology namely, nucleic acids, including plasmids for development of therapeutics and the treatment of central nervous system, neurological, and peripheral nervous system diseases and disorders |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 6, 2020 |
| Primary Code | 001 |
| First Use Anywhere Date | Friday, July 5, 2024 |
| First Use In Commerce Date | Friday, July 5, 2024 |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 6, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | Thursday, August 14, 2025 |
| First Use In Commerce Date | Thursday, August 14, 2025 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 6, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | Monday, April 17, 2023 |
| First Use In Commerce Date | Monday, April 17, 2023 |
| Party Name | CAPSIDA BIOTHERAPEUTICS, INC. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Thousand Oaks, CA 91320 US |
| Party Name | CAPSIDA BIOTHERAPEUTICS, INC. |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Thousand Oaks, CA 91320 US |
| Party Name | Capsida, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Westlake Village, CA 91361 US |
| Event Date | Event Description |
| Tuesday, July 14, 2020 | NEW APPLICATION ENTERED |
| Thursday, August 6, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, October 21, 2020 | ASSIGNED TO EXAMINER |
| Saturday, October 24, 2020 | NON-FINAL ACTION WRITTEN |
| Saturday, October 24, 2020 | NON-FINAL ACTION E-MAILED |
| Saturday, October 24, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, November 4, 2020 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Friday, December 4, 2020 | NON-FINAL ACTION WRITTEN |
| Friday, December 4, 2020 | NON-FINAL ACTION E-MAILED |
| Friday, December 4, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, May 27, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, May 27, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, May 28, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, June 1, 2021 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, June 1, 2021 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, June 1, 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, June 1, 2021 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, June 1, 2021 | SUSPENSION LETTER WRITTEN |
| Tuesday, June 1, 2021 | LETTER OF SUSPENSION E-MAILED |
| Tuesday, June 1, 2021 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Wednesday, December 1, 2021 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Wednesday, March 16, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, March 16, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, March 16, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, June 21, 2022 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Thursday, June 23, 2022 | NON-FINAL ACTION WRITTEN |
| Thursday, June 23, 2022 | NON-FINAL ACTION E-MAILED |
| Thursday, June 23, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, December 21, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, December 21, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, December 21, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, January 5, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, January 18, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, February 7, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, February 7, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 4, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, September 27, 2023 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, September 27, 2023 | SOU EXTENSION 1 FILED |
| Wednesday, September 27, 2023 | SOU EXTENSION 1 GRANTED |
| Friday, September 29, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, March 4, 2024 | SOU TEAS EXTENSION RECEIVED |
| Monday, March 4, 2024 | SOU EXTENSION 2 FILED |
| Monday, March 4, 2024 | SOU EXTENSION 2 GRANTED |
| Tuesday, March 5, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, October 1, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, October 1, 2024 | SOU EXTENSION 3 FILED |
| Tuesday, October 1, 2024 | SOU EXTENSION 3 GRANTED |
| Tuesday, October 1, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, March 28, 2025 | SOU TEAS EXTENSION RECEIVED |
| Friday, March 28, 2025 | SOU EXTENSION 4 FILED |
| Saturday, March 29, 2025 | SOU EXTENSION 4 GRANTED |
| Saturday, March 29, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, October 3, 2025 | SOU TEAS EXTENSION RECEIVED |
| Friday, October 3, 2025 | TEAS STATEMENT OF USE RECEIVED |
| Friday, October 3, 2025 | SOU EXTENSION 5 FILED |
| Friday, March 6, 2026 | SOU EXTENSION 5 GRANTED |
| Friday, October 3, 2025 | USE AMENDMENT FILED |
| Friday, March 6, 2026 | STATEMENT OF USE PROCESSING COMPLETE |
| Saturday, March 7, 2026 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |